Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

ween pirfenidone and placebo in the percentage of patients that experienced a serious adverse event (SAE) and the pattern of adverse events (AEs) was, in general, comparable to that observed in previous clinical studies of pirfenidone.
  • InterMune is preparing an NDA for submission to the FDA in the summer of 2009, to be followed by an MAA submission to the European Medicines Agency (EMEA) around the end of 2009.
  • Results from the CAPACITY studies will be presented in an oral late-breaker session at 3:35 p.m. PDT on May 19 at the International Conference of the American Thoracic Society (ATS) in San Diego.

  • ITMN-191:

    • On January 12, InterMune announced top-line results from a 14-day, Phase 1b study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin).
      • After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. ITMN-191 delivered viral kinetic performance that is comparable to the best results reported to date for other protease inhibitors in similar experiments.
      • There was no evidence of viral rebound during ITMN-191 treatment in any cohort.
      • On April 24, InterMune reported that data from the triple combination study had informed the dose selection for the Phase 2b program of ITMN-191. The Phase 2b trial, expected to begin in the summer of 2009, will study both q12h regimens (600mg and 900mg q12h) and a q8h regimen (300mg q8h) and both 12-week and 24-week treatment durations.

    • At the Annual Meeting of the European Association for the Study of the Liver (EASL
      '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. InterMune to Release First Quarter Financial Results on April 30
    2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    3. InterMune to Present at Canaccord Adams Hepatitis C Conference
    4. InterMune to Present at Citis 4th Annual Biotech Day
    5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    8. InterMune Announces Issuance of U.S. Patent for ITMN-191
    9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
    10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
    11. InterMune to Present at J.P. Morgan Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
    (Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
    (Date:7/1/2015)... , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite   ... technical and medical information products and services, announced today the ... clinical decision support (CDS) technology company. InferMed,s Arezzo ...
    (Date:6/30/2015)... R-Japan Co.,Ltd. obtained the license of cell processing ... from the Ministry of Health, Labour and Welfare Kinki Bureau ... The fact that R- Japan received ... Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 ... stem cell manufacturing service to medical institutions. As of November ...
    Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
    ... Group today released its syndicated report TreatmentTrends ... the fourth annual survey of U.S. Dermatologists (n=150). The ... April, highlights shifting trends in the management of psoriasis and ... mild, moderate, and severe patients with an emphasis on the ...
    ... GAITHERSBURG, Md., May 28 GenVec, Inc. (Nasdaq: ... purchase agreement with a single institutional investor for the sale of ... shares of its common stock. The shares of common stock ... of common stock and a warrant to purchase one share of ...
    ... researchers at the University of Illinois has demonstrated that, ... superconducting electrons in an ultrathin superconducting wire is able ... a higher electrical current to one with a notably ... macroscopic quantum tunneling. , Physics professors Alexey Bezryadin and ...
    Cached Biology Technology:Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3Evidence of macroscopic quantum tunneling detected in nanowires 2
    (Date:6/23/2015)... 2015 Research and ... the "Body-Worn Temperature Sensors Market - Global ... 2014 - 2020" report to their offering. ... the global body-worn temperature sensors market. The global ... the basis of types, care setting, patient demographic, ...
    (Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
    (Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
    Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
    ... Millions of patients suffering from liver,damage (cirrhosis) and ... Edinburgh and Southampton which may lead to new,life-saving ... cirrhosis,and a patient's only hope of survival is ... the University's Centre for Inflammation,Research, in collaboration with ...
    ... of Oregon have,discovered a form of blue-green algae ... light for photosynthesis,according to an article published in ... National Academy of Sciences (PNAS).,"This new strain of ... live,on its own," says UO biology professor Michelle ...
    ... work, scientists have now found that changes in a single ... fish living in the wild. , The surprising results, announced ... new data to long-standing debates about how evolution occurs in ... how new animal types evolve in nature," said molecular geneticist ...
    Cached Biology News:Research Gives Hope For Liver Damage 2Scientists discover unique microbe in California's largest lake 2Scientists discover unique microbe in California's largest lake 3Scientists discover unique microbe in California's largest lake 4Scientists discover unique microbe in California's largest lake 5Octopuses occasionally stroll around on two arms, UC Berkeley biologists report 2Octopuses occasionally stroll around on two arms, UC Berkeley biologists report 3Octopuses occasionally stroll around on two arms, UC Berkeley biologists report 4Octopuses occasionally stroll around on two arms, UC Berkeley biologists report 5